论文部分内容阅读
The recent discovery of immune checkpoints inhibitors,especially anti-programmed cell death protein 1(PD-1)and anti-programmed cell death protein ligand 1(PD-L1)monoclonal antibodies,has opened new scenarios in the management of non-small cell lung cancer